RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
By Elana Gotkine HealthDay Reporter
TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7 months during the 2024-2025 RSV season, the first season that the maternal vaccine and nirsevimab were widely available, according to research published in the May 8 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Monica E. Patton, M.D., from the CDC in Atlanta, and colleagues used data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN) to examine the association between availability of maternal RSV vaccine and nirsevimab and infant and child RSV-associated hospitalization rates by comparing the rates among children aged younger than 5 years for the 2024-2025 and 2018-2020 RSV seasons.
The researchers found that compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months (eligible for protection with maternal vaccination or nirsevimab; estimated rate reductions of 43 and 28 percent for RSV-NET and NVSN, respectively). Infants aged 0 to 2 months had the largest estimated rate reduction (52 and 45 percent for RSV-NET and NVSN, respectively); large reductions were also seen during peak hospitalization periods (December to February).
"These findings highlight the importance of effective annual health care planning to implement Advisory Committee on Immunization Practices' recommendations for RSV prevention products and ensure parents can protect infants as early as possible in the RSV season, either through maternal vaccination during pregnancy or infant receipt of nirsevimab," the authors write. "For infants born during the RSV season who are not protected through maternal vaccination, nirsevimab should be administered within the first week of life, ideally during the birth hospitalization."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and...
Live Zoster Vaccination Linked to Lower Risk for Cardiovascular Events
THURSDAY, May 8, 2025 -- Live zoster vaccination is associated with a lower risk for overall cardiovascular events when compared with no vaccination, according to a study...
Nirsevimab Effective for Reducing Burden of RSV in Infants
THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.